Decreased Serum Albumin Predicts Bleeding Events in Patients on Antiplatelet Therapy After Percutaneous Coronary Intervention

Background:Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association...

Full description

Saved in:
Bibliographic Details
Published inCirculation Journal Vol. 81; no. 7; pp. 999 - 1005
Main Authors Tatami, Yosuke, Ishii, Hideki, Aoki, Toshijiro, Harada, Kazuhiro, Hirayama, Kenshi, Shibata, Yohei, Sumi, Takuya, Negishi, Yosuke, Kawashima, Kazuhiro, Kunimura, Ayako, Kawamiya, Toshiki, Yamamoto, Dai, Suzuki, Susumu, Murohara, Toyoaki
Format Journal Article
LanguageEnglish
Published Japan The Japanese Circulation Society 2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background:Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association between serum albumin level and bleeding events in this population.Methods and Results:We enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and thienopyridine) beyond 1 month after successful PCI without adverse events. The patients were divided into 3 groups according to serum albumin tertile: tertile 1, ≤3.7 g/dL; tertile 2, 3.8–4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding events were defined as Bleeding Academic Research Consortium criteria types 2, 3, and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding events were observed. Median duration of DAPT was 14 months. The tertile 1 group had the highest risk of adverse bleeding events (event-free rate, 83.1%, 94.3% and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 0.027–0.39, P=0.001, for tertile 3 vs. tertile 1).Conclusions:Decreased serum albumin predicted bleeding events in patients with APT after PCI.
AbstractList Background:Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association between serum albumin level and bleeding events in this population.Methods and Results:We enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and thienopyridine) beyond 1 month after successful PCI without adverse events. The patients were divided into 3 groups according to serum albumin tertile: tertile 1, ≤3.7 g/dL; tertile 2, 3.8–4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding events were defined as Bleeding Academic Research Consortium criteria types 2, 3, and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding events were observed. Median duration of DAPT was 14 months. The tertile 1 group had the highest risk of adverse bleeding events (event-free rate, 83.1%, 94.3% and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 0.027–0.39, P=0.001, for tertile 3 vs. tertile 1).Conclusions:Decreased serum albumin predicted bleeding events in patients with APT after PCI.
Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association between serum albumin level and bleeding events in this population.Methods and Results:We enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and thienopyridine) beyond 1 month after successful PCI without adverse events. The patients were divided into 3 groups according to serum albumin tertile: tertile 1, ≤3.7 g/dL; tertile 2, 3.8-4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding events were defined as Bleeding Academic Research Consortium criteria types 2, 3, and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding events were observed. Median duration of DAPT was 14 months. The tertile 1 group had the highest risk of adverse bleeding events (event-free rate, 83.1%, 94.3% and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 0.027-0.39, P=0.001, for tertile 3 vs. tertile 1). Decreased serum albumin predicted bleeding events in patients with APT after PCI.
BACKGROUNDAntiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association between serum albumin level and bleeding events in this population.Methods and Results:We enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and thienopyridine) beyond 1 month after successful PCI without adverse events. The patients were divided into 3 groups according to serum albumin tertile: tertile 1, ≤3.7 g/dL; tertile 2, 3.8-4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding events were defined as Bleeding Academic Research Consortium criteria types 2, 3, and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding events were observed. Median duration of DAPT was 14 months. The tertile 1 group had the highest risk of adverse bleeding events (event-free rate, 83.1%, 94.3% and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 0.027-0.39, P=0.001, for tertile 3 vs. tertile 1).CONCLUSIONSDecreased serum albumin predicted bleeding events in patients with APT after PCI.
Author Ishii, Hideki
Sumi, Takuya
Aoki, Toshijiro
Tatami, Yosuke
Yamamoto, Dai
Kawamiya, Toshiki
Hirayama, Kenshi
Shibata, Yohei
Kawashima, Kazuhiro
Kunimura, Ayako
Harada, Kazuhiro
Suzuki, Susumu
Negishi, Yosuke
Murohara, Toyoaki
Author_xml – sequence: 1
  fullname: Tatami, Yosuke
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 2
  fullname: Ishii, Hideki
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 3
  fullname: Aoki, Toshijiro
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 4
  fullname: Harada, Kazuhiro
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 5
  fullname: Hirayama, Kenshi
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 6
  fullname: Shibata, Yohei
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 7
  fullname: Sumi, Takuya
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 8
  fullname: Negishi, Yosuke
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 9
  fullname: Kawashima, Kazuhiro
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 10
  fullname: Kunimura, Ayako
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 11
  fullname: Kawamiya, Toshiki
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 12
  fullname: Yamamoto, Dai
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 13
  fullname: Suzuki, Susumu
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
– sequence: 14
  fullname: Murohara, Toyoaki
  organization: Department of Cardiology, Nagoya University Graduate School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28344205$$D View this record in MEDLINE/PubMed
BookMark eNpFkElP5DAQha0RiG24z2nkI5eAtyTOsQm7kECCOVuOXQG3EqfHdpA48N9Juhu4VL1SffVUeodoxw8eEPpDySllOT8zLpjlaX2X0TIjhOa_0AHlosyEZGRnrYuskoLvo8MYl4SwiuTVHtpnkgvBSH6APi7ABNARLH6CMPZ40TVj7zx-DGCdSRGfdzAp_4Iv38BP87zTya314PHCJ7fqdIIOEn5-haBX73jRJgj4EYIZk_YwjBHXQxi8Du_41k-72coN_jfabXUX4Xjbj9C_q8vn-ia7f7i-rRf3mSkYSxlIAtaUvGUVmEbnrRSNsK1tDIOSklJXkgLV3GgBljZ5Ia21omDQcAHCan6ETja-qzD8HyEm1btooOs2zykqJRWiFLyYULJBTRhiDNCqVXD99LiiRM2hq3Xoqr5TtFRz6NPJ36372PRgvw--Up6Aqw2wjEm_wDegQ3Kmg62jpKqcy4_zD_CqgwLPPwH2-506
CitedBy_id crossref_primary_10_1016_j_amjcard_2023_02_027
crossref_primary_10_5551_jat_47654
crossref_primary_10_1016_j_amjcard_2021_10_043
crossref_primary_10_1016_j_ijcard_2021_11_046
crossref_primary_10_1016_j_numecd_2022_01_016
crossref_primary_10_1111_eci_13789
crossref_primary_10_3390_ijms24087375
crossref_primary_10_2139_ssrn_3935603
crossref_primary_10_1007_s11239_020_02092_w
crossref_primary_10_1007_s11239_018_1707_1
crossref_primary_10_1016_j_jjcc_2018_12_009
crossref_primary_10_1016_j_injury_2017_08_060
crossref_primary_10_1016_j_jjcc_2018_10_013
crossref_primary_10_1016_j_ijcard_2020_10_015
Cites_doi 10.1001/jama.1994.03520130074036
10.1056/NEJMoa1409312
10.2307/2531595
10.1161/CIRCULATIONAHA.110.009449
10.3945/an.111.001800
10.1161/CIRCULATIONAHA.111.071589
10.1016/j.jacc.2014.11.008
10.1161/01.CIR.0000042673.07632.76
10.2215/CJN.09260913
10.1002/sim.2929
10.1097/MCA.0b013e32835c46fd
10.1093/oxfordjournals.aje.a010232
10.1111/j.1523-1755.2004.00520.x
10.1146/annurev.med.51.1.245
10.1111/j.0894-0959.2004.17603.x
10.1111/j.1523-1755.2005.00455.x
10.1016/j.jacc.2012.06.043
10.1016/S0140-6736(14)62052-3
10.1253/circj.CJ-09-0498
10.1111/j.1532-5415.1999.tb01583.x
10.1016/j.euje.2005.12.014
10.1055/s-0041-111499
10.1001/jama.2016.3775
10.1016/j.jacc.2015.01.039
10.1016/j.ajem.2016.06.049
10.1111/j.1532-5415.2005.53369.x
10.1053/j.ajkd.2008.12.034
10.1016/j.ahj.2007.11.043
10.1016/j.mam.2011.12.002
10.1046/j.1365-2141.1996.5101050.x
10.1177/014860719702100281
ContentType Journal Article
Copyright 2017 THE JAPANESE CIRCULATION SOCIETY
Copyright_xml – notice: 2017 THE JAPANESE CIRCULATION SOCIETY
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1253/circj.CJ-17-0015
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1347-4820
EndPage 1005
ExternalDocumentID 10_1253_circj_CJ_17_0015
28344205
article_circj_81_7_81_CJ_17_0015_article_char_en
Genre Clinical Trial
Journal Article
Observational Study
GroupedDBID ---
.55
29B
2WC
53G
5GY
5RE
6J9
AAUGY
ACGFO
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
JSF
JSH
KQ8
M~E
OK1
P2P
RJT
RNS
RZJ
TR2
W2D
X7M
XSB
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
.GJ
3O-
AAYXX
CITATION
RYR
TKC
7X8
ID FETCH-LOGICAL-c622t-e80edc73f29ecba5f84b4dfdbc2e7107a981e1a3ca4ed1b568ddd462eb34e4da3
ISSN 1346-9843
IngestDate Sun May 12 02:42:38 EDT 2024
Fri Aug 23 02:59:08 EDT 2024
Fri May 24 00:03:53 EDT 2024
Thu Aug 17 20:29:17 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Antiplatelet therapy
Albumin
Bleeding event
Percutaneous coronary intervention
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c622t-e80edc73f29ecba5f84b4dfdbc2e7107a981e1a3ca4ed1b568ddd462eb34e4da3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.jstage.jst.go.jp/article/circj/81/7/81_CJ-17-0015/_article/-char/en
PMID 28344205
PQID 1881447436
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_1881447436
crossref_primary_10_1253_circj_CJ_17_0015
pubmed_primary_28344205
jstage_primary_article_circj_81_7_81_CJ_17_0015_article_char_en
PublicationCentury 2000
PublicationDate 2017-00-00
PublicationDateYYYYMMDD 2017-01-01
PublicationDate_xml – year: 2017
  text: 2017-00-00
PublicationDecade 2010
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle Circulation Journal
PublicationTitleAlternate Circ J
PublicationYear 2017
Publisher The Japanese Circulation Society
Publisher_xml – name: The Japanese Circulation Society
References 4. Sullivan DH, Roberson PK, Bopp MM. Hypoalbuminemia 3 months after hospital discharge: Significance for long-term survival. J Am Geriatr Soc 2005; 53: 1222–1226.
17. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al; RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (Real Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012; 60: 1340–1348.
28. Kim BC, Cheon JH, Kim TI, Kim WH. Risk factors and the role of bedside colonoscopy for lower gastrointestinal hemorrhage in critically ill patients. Hepatogastroenterology 2008; 55: 2108–2111.
15. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172.
8. Liang CC, Wang SM, Kuo HL, Chang CT, Liu JH, Lin HH, et al. Upper gastrointestinal bleeding in patients with CKD. Clin J Am Soc Nephrol 2014; 9: 1354–1359.
24. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000; 51: 245–270.
3. Corti MC, Guralnik JM, Salive ME, Sorkin JD. Serum albumin level and physical disability as predictors of mortality in older persons. JAMA 1994; 272: 1036–1042.
29. Oduncu V, Erkol A, Karabay CY, Kurt M, Akgün T, Bulut M, et al. The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis 2013; 24: 88–94.
25. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999; 47: 639–646.
2. Yeh RW, Secemsky EA, Kereiakes DJ, Normand ST, Gershlick AH, Cohen DJ, et al; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016; 315: 1735–1749.
5. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766–772.
31. Ben-Zvi GT, Tidman MJ. Be vigilant for scurvy in high-risk groups. Practitioner 2012; 256: 23–25.
18. Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: The randomized, multicenter ITALIC trial. J Am Coll Cardiol 2015; 65: 777–786.
19. Elmariah S, Mauri L, Doros G, Galper BZ, O’Neill KE, Steg PG, et al. Extended duration dual antiplatelet therapy and mortality: A systematic review and meta-analysis. Lancet 2015; 385: 792–798.
22. Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: From bench to bedside. Mol Aspects Med 2012; 33: 209–290.
13. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736–2747.
9. Cheng HC, Wu CT, Chen WY, Yang EH, Chen PJ, Sheu BS. Risk factors determining the need for second-look endoscopy for peptic ulcer bleeding after endoscopic hemostasis and proton pump inhibitor infusion. Endosc Int Open 2016; 4: E255–E262.
10. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992.
33. Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Littlewood TJ. The incidence and cause of coagulopathies in an intensive care population. Br J Haematol 1996; 93: 460–463.
27. Zhang Q, Lei YX, Wang Q, Jin YP, Fu RL, Geng HH, et al. Serum albumin level is associated with the recurrence of acute ischemic stroke. Am J Emerg Med 2016; 34: 1812–1816.
6. Djoussé L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation 2002; 106: 2919–2924.
16. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 2012; 125: 2015–2026.
20. Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: A systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2015; 65: 1298–1310.
23. Kaysen GA, Dubin JA, Müller HG, Rosales L, Levin NW, Mitch WE; HEMO Study Group NIDDK. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 2004; 65: 1408–1415.
14. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837–845.
7. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008; 155: 883–889.
32. Shearer MJ, Fu X, Booth SL. Vitamin K nutrition, metabolism, and requirements: Current concepts and future research. Adv Nutr 2012; 3: 182–195.
30. Rady MY, Ryan T, Starr NJ. Clinical characteristics of preoperative hypoalbuminemia predict outcome of cardiovascular surgery. JPEN J Parenter Enteral Nutr 1997; 21: 81–90.
21. Don BR, Kaysen G. Serum albumin: Relationship to inflammation and nutrition. Semin Dial 2004; 17: 432–437.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al; American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79–108.
26. Nelson JJ, Liao D, Sharrett AR, Folsom AR, Chambless LE, Shahar E, et al. Serum albumin level as a predictor of incident coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 468–477.
1. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–2166.
11. Kinugasa Y, Kato M, Sugihara S, Hirai M, Kotani K, Ishida K, et al. A simple risk score to predict in-hospital death of elderly patients with acute decompensated heart failure: Hypoalbuminemia as an additional prognostic factor. Circ J 2009; 73: 2276–2281.
22
23
24
25
26
27
28
29
30
31
10
32
11
33
12
13
14
15
16
17
18
19
1
2
3
4
5
6
7
8
9
20
21
References_xml – ident: 3
  doi: 10.1001/jama.1994.03520130074036
– ident: 1
  doi: 10.1056/NEJMoa1409312
– ident: 14
  doi: 10.2307/2531595
– ident: 13
  doi: 10.1161/CIRCULATIONAHA.110.009449
– ident: 32
  doi: 10.3945/an.111.001800
– ident: 16
  doi: 10.1161/CIRCULATIONAHA.111.071589
– ident: 18
  doi: 10.1016/j.jacc.2014.11.008
– ident: 6
  doi: 10.1161/01.CIR.0000042673.07632.76
– ident: 8
  doi: 10.2215/CJN.09260913
– ident: 15
  doi: 10.1002/sim.2929
– ident: 29
  doi: 10.1097/MCA.0b013e32835c46fd
– ident: 31
– ident: 26
  doi: 10.1093/oxfordjournals.aje.a010232
– ident: 23
  doi: 10.1111/j.1523-1755.2004.00520.x
– ident: 24
  doi: 10.1146/annurev.med.51.1.245
– ident: 28
– ident: 21
  doi: 10.1111/j.0894-0959.2004.17603.x
– ident: 5
  doi: 10.1111/j.1523-1755.2005.00455.x
– ident: 17
  doi: 10.1016/j.jacc.2012.06.043
– ident: 19
  doi: 10.1016/S0140-6736(14)62052-3
– ident: 11
  doi: 10.1253/circj.CJ-09-0498
– ident: 25
  doi: 10.1111/j.1532-5415.1999.tb01583.x
– ident: 12
  doi: 10.1016/j.euje.2005.12.014
– ident: 9
  doi: 10.1055/s-0041-111499
– ident: 2
  doi: 10.1001/jama.2016.3775
– ident: 20
  doi: 10.1016/j.jacc.2015.01.039
– ident: 27
  doi: 10.1016/j.ajem.2016.06.049
– ident: 4
  doi: 10.1111/j.1532-5415.2005.53369.x
– ident: 10
  doi: 10.1053/j.ajkd.2008.12.034
– ident: 7
  doi: 10.1016/j.ahj.2007.11.043
– ident: 22
  doi: 10.1016/j.mam.2011.12.002
– ident: 33
  doi: 10.1046/j.1365-2141.1996.5101050.x
– ident: 30
  doi: 10.1177/014860719702100281
SSID ssj0029059
Score 2.2838058
Snippet Background:Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known...
Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the...
BACKGROUNDAntiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known...
SourceID proquest
crossref
pubmed
jstage
SourceType Aggregation Database
Index Database
Publisher
StartPage 999
SubjectTerms Aged
Aged, 80 and over
Albumin
Antiplatelet therapy
Aspirin - administration & dosage
Aspirin - adverse effects
Bleeding event
Female
Humans
Male
Middle Aged
Percutaneous coronary intervention
Percutaneous Coronary Intervention - adverse effects
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - adverse effects
Postoperative Hemorrhage - blood
Postoperative Hemorrhage - epidemiology
Postoperative Hemorrhage - etiology
Pyridines - administration & dosage
Pyridines - adverse effects
Risk Factors
Serum Albumin, Human - metabolism
Time Factors
Title Decreased Serum Albumin Predicts Bleeding Events in Patients on Antiplatelet Therapy After Percutaneous Coronary Intervention
URI https://www.jstage.jst.go.jp/article/circj/81/7/81_CJ-17-0015/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/28344205
https://search.proquest.com/docview/1881447436
Volume 81
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Circulation Journal, 2017/06/23, Vol.81(7), pp.999-1005
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaqBSEuiDflJSNxQVWWxHES54RKWbRUAnHoSuUUJbZD04UUZVsOK_Fb-SvM2M6DhUosF6uKEzfJfJkZ29_MEPKcS66TQsUeplr3eOQrT7C89Pw8KkuZMBFLQ5D9EB-f8PkyWo5GPwespd22OJTnf40r-R-pwjGQK0bJXkKy3aBwAH6DfKEFCUP7TzJ-Y3y-M_QZdYMr7bjeXtXIq1AVsjRef7HGaXL03USyYZ9NpGp2CaY1kgnB2wThIfcC8wtMpqZq-EfdyB04jhopsjNMc4D0uncDhuTQrZ1VjXR1wLpcFPsSVKCnOwcTjaUvJ8MLHYG0X0vY5l8N1-DT5mx3qnsQrypbartS-rTqELuxBbgXG-hfV82m161Nrlzg2_lu1fa4lQ4b0unUcshjLxU2odOhbo8lHhfMH-pyW_7FYTYZKObUlmFyNj7wTaz3n_aDmSIgEp59fTibe2DB0ansbWXLD7hgQjtiI06pYIzMjJDN5lmA2_uYBOEKw0yEGI2-7DhILPVNNb_u8dw-Oozw8uI9_OY3XV3D1OGz3j8rMt7R4ia54aY1dGoxeouMdH2bXHvviBt3yI8OqtRAlTqo0haqtIUqtVCl2OegSjc1HUKVOqhSA1U6hCptoUqHUL1LTt4eLWbHnqv84cmYsa2nha-VTMKSpVoWoDYEL7gqVSGZBpc4yVMR6CAPZc61CoooFkopHjNdhFxzlYf3yEG9qfUDQkWCFQ1SXeq04CIt4Io4EEoneSFSFUZj8qJ9r9k3m-Al2yfFMXllX3x3pvv03ZkiyBJs-iv6E1Z5AyprTJ61EstAj-PmnH09WSBEwDn48_GY3Lei7P6FYTEc5kcPL3Gvj8h1_IbsauFjcrBtdvoJ-M_b4qnB4C_pL9Du
link.rule.ids 315,783,787,4033,27937,27938,27939
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+Serum+Albumin+Predicts+Bleeding+Events+in+Patients+on+Antiplatelet+Therapy+After+Percutaneous+Coronary+Intervention&rft.jtitle=Circulation+journal+%3A+official+journal+of+the+Japanese+Circulation+Society&rft.au=Tatami%2C+Yosuke&rft.au=Ishii%2C+Hideki&rft.au=Aoki%2C+Toshijiro&rft.au=Harada%2C+Kazuhiro&rft.date=2017&rft.issn=1346-9843&rft.eissn=1347-4820&rft.volume=81&rft.issue=7&rft.spage=999&rft.epage=1005&rft_id=info:doi/10.1253%2Fcircj.CJ-17-0015&rft.externalDBID=n%2Fa&rft.externalDocID=10_1253_circj_CJ_17_0015
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-9843&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-9843&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-9843&client=summon